



Proposed asset

- Domain name: GenomicSovereignty.com (.com, exact-match)
- Nature: descriptive digital asset designed as a neutral banner for “genomic sovereignty”:
the ability of States, peoples, regions or alliances to govern access to, use of and benefit-sharing around genomic resources and data (human and non-human).

Not included:

- No biobank, no genetic database, no sequencing platform, no medical service.
- No ownership of any population’s genes or samples.
- No regulatory mandate, no affiliation with any government, indigenous organisation, or international body.

Contacts

- Website: <https://www.genomicsovereignty.com>
- Email: contact@genomicsovereignty.com
- LinkedIn: <https://www.linkedin.com/company/genomicsovereignty>

This brief — for whom, for what

Intended for:

- Ministries and agencies: health, research, digital, indigenous affairs, foreign affairs.
- International organisations: WHO, UNESCO, regional organisations, global alliances.
- Large research consortia & biobanks: national genome projects, public–private partnerships.
- Philanthropies & foundations: global health, genomics, data governance, indigenous rights.

Objective: provide board-level decision-makers with a clear view of the strategic value and safe use of GenomicSovereignty.com as a neutral, category-defining banner for genomic data governance debates and initiatives.

1) One-page decision

What GenomicSovereignty.com is

- A .com exact-match name encapsulating the term already present in laws, academic debates and policy documents.
- A neutral surface to host frameworks, observatories, alliances and principles concerning genomic data governance and the rights of peoples and individuals.

What it is *not*

To minimise legal and ethical risk, this brief states explicitly that GenomicSovereignty.com:

- is **not** a claim of ownership over any genome, population, or resource;
- is **not** a biobank, a medical service, nor a provider of genetic testing;
- is **not** an official agency, ethics committee, or governmental body;
- does **not** take a normative position “for” or “against” any specific law — it provides language and space for debate.

What the acquirer can do with it

- Make it the banner of a *Genomic Sovereignty & Data Governance* initiative, alliance or observatory.
 - Use it as the public interface for reports, principles, capacity-building and best practices on genomic data governance.
 - Anchor a multi-stakeholder network (States, researchers, indigenous organisations, civil society, private sector) around a name that is descriptive, not proprietary.
-

2) 2025–2035 context — why “genomic sovereignty” rises

Key trends:

1. Explosion of biobanks and mass sequencing

National genome programmes, regional biobanks, and large-scale private datasets are reshaping research and healthcare — often with cross-border flows of samples and data.

2. **AI × genomics**

Advanced AI models trained on genomic and health data raise complex questions around consent, reuse, bias, and benefit-sharing across borders.

3. **Global South & indigenous claims**

Countries and indigenous peoples increasingly demand control over genomic resources and data, invoking genomic sovereignty to avoid extractive, one-sided arrangements.

4. **Regulatory and ethical fragmentation**

Different national laws, treaties and soft-law instruments are emerging, with diverging interpretations of sovereignty, human rights, and data governance.

Whether one supports or contests the term, *genomic sovereignty* will structure debates, legislation and funding on genomics in the coming decade. GenomicSovereignty.com is the natural banner for these discussions.

3) Problems & tensions to address

1. **Power asymmetries**

- Samples and data often collected in low-resource settings, analysed and monetised elsewhere.
- Limited technology transfer and local capacity-building.

2. **Rights of individuals and peoples**

- Inadequate informed consent for long-term, AI-enabled, cross-border uses.
- Fears of discrimination, stigmatisation or surveillance based on genetic traits.

3. **Regulatory fragmentation**

- Patchwork of national laws on data protection, health data, genetic resources.
- Little shared language to build interoperable, rights-respecting frameworks.

GenomicSovereignty.com offers a neutral label under which to document these tensions, propose principles, and convene stakeholders.

4) Illustrative use cases / scenarios

(All scenarios are illustrative, not binding.)

Scenario A — Global think tank / observatory

- Public portal hosting:
 - comparative mapping of national policies,
 - case studies,
 - guidelines and research outputs on genomic data governance and sovereignty.

Scenario B — Multi-region alliance

- A South–South or regionally anchored alliance (e.g. Africa / Latin America / Asia) using GenomicSovereignty.com as the joint banner for:
 - capacity-building, infrastructure funding,
 - data localisation policies,
 - shared principles on AI in genomics and benefit-sharing.

Scenario C — Ethical & legal framework hub

- Reference site for principles such as genomic solidarity vs genomic sovereignty, benefit-sharing, dynamic consent, data trusts and stewardship models.

Scenario D — Interface to AI in genomics

- Label for standards and labels ensuring that AI models trained on genomic data respect human rights, indigenous rights and global health goals.

5) Target buyers & sponsors

- **International organisations** — WHO, UNESCO, regional organisations needing a neutral digital banner for programmes on genomics & rights.
- **Governments & public agencies** — ministries of health, research, digital, indigenous affairs.
- **Large foundations & philanthropies** — funding genomic and data governance initiatives.
- **Academic consortia & biobanks** — national genome projects, regional collaborations.
- **Indigenous & community organisations** — as co-owners or key partners in a governance structure.

6) Position within a broader portfolio

GenomicSovereignty.com complements:

- **XGenetics.ai / XGenomics.ai** — technological & analytical layer for genomics and AI.
- **ModelSovereignty.com** — sovereignty over AI models trained (in part) on genomic

data.

- **LivingProcessor.com** — narrative on future bio-inspired and organoid-based compute, which will increasingly rely on sensitive biological data.

Suggested positioning:

“GenomicSovereignty.com sits upstream of ModelSovereignty.com: before discussing sovereignty over AI models in health, one must clarify who governs the genomic data that feed them.”

Related assets / optional bundle (≤2, not included by default)

- ModelSovereignty.com — banner for sovereignty over AI models and weights.
 - XGenomics.ai — AI/genomics technology layer (example of a complementary tech asset).
-

7) Legal & ethical guardrails

To remain strictly within a safe, rights-respecting perimeter:

GenomicSovereignty.com **must not be used** to:

- claim ownership of any population’s genes, genomes or bodies;
- offer diagnostic, therapeutic or genetic testing services without appropriate licensing;
- impersonate any State, indigenous authority, ethics committee or regulator;
- encourage discriminatory or harmful uses of genomic information.

This brief:

- describes a *descriptive digital asset* only;
- is not medical, legal, financial or regulatory advice;
- does not guarantee compliance with any law, treaty or ethical guideline.

The acquirer bears full responsibility for:

- governance structures (including representation of indigenous and affected communities),
 - all content, tools and programmes operated under GenomicSovereignty.com,
 - compliance with human rights, data protection, health, research and indigenous rights law in all relevant jurisdictions.
-

8) Acquisition process (indicative)

1. Initial contact via contact@genomicsovereignty.com (professional, identified).
 2. Optional NDA, with explicit mention of ethical and human-rights safeguards.
 3. Strategic discussion: purpose (observatory, alliance, programme), governance, representation of affected communities.
 4. Formal offer (scope, price, calendar, possible bundle with complementary assets).
 5. Escrow-based transaction and transfer to buyer's registrar.
 6. Communication (public launch or discreet acquisition), aligned with participating communities and partners.
-